Europe — EMA
Hefiya (Adalimumab)
Learn about Hefiya adalimumab, a subcutaneous TNF‑α inhibitor approved in the EU for rheumatoid arthritis, psoriasis, Crohn’s disease, and other autoimmune disorders.
Request sourcing
What is Adalimumab?
Hefiya is a prescription medication that contains the active ingredient adalimumab, a biologic TNF‑α inhibitor administered by subcutaneous injection. Marketed in the European Union, Hefiya is supplied in a solution for self‑injection, though specific strength details are not publicly disclosed. It belongs to the immunosuppressant class and is used to reduce inflammation in several autoimmune disorders. The product is intended for adult patients under medical supervision.
What is Adalimumab used for?
Hefiya is indicated for the treatment of several chronic inflammatory and autoimmune conditions.
- Rheumatoid arthritis - Psoriatic arthritis - Ankylosing spondylitis - Inflammatory bowel disease (Crohn’s disease and ulcerative colitis) - Plaque psoriasis - Hidradenitis suppurativa
What are the side effects of Adalimumab?
Adalimumab may cause a range of adverse effects, which are generally categorized as common or serious.
Common: - Injection‑site pain, redness, or swelling - Upper respiratory tract infections (e.g., sinusitis, nasopharyngitis) - Headache - Mild skin rash or itching
Serious: - Severe infections such as tuberculosis or opportunistic fungal infections - Malignancies, including lymphoma and skin cancers - Demyelinating disorders of the central nervous system - New or worsening heart failure
What precautions apply to Adalimumab?
Before initiating Hefiya, clinicians should evaluate patients for conditions that could increase risk during therapy.
- Screen for latent tuberculosis and treat before starting therapy - Assess hepatitis B status and vaccinate if non‑immune - Review history of recurrent or chronic infections - Consider potential risks in pregnancy, lactation, and women of child‑bearing age - Monitor for signs of malignancy or demyelinating disease - Use caution in patients with moderate to severe congestive heart failure
What does Adalimumab interact with?
Adalimumab can interact with other medicines, requiring careful management.
Avoid: - Concurrent use of live vaccines (e.g., yellow fever, BCG) - Other biologic agents that target TNF‑α or the immune system
Use with caution: - Immunosuppressants such as methotrexate, azathioprine, or cyclophosphamide - Systemic corticosteroids, especially at high doses - Vaccinations that are not live (e.g., influenza, pneumococcal) – timing should be coordinated - Scheduled surgeries or invasive dental procedures - Antiviral therapies for chronic hepatitis B
